1223 related articles for article (PubMed ID: 26809026)
21. The biology and management of systemic anaplastic large cell lymphoma.
Hapgood G; Savage KJ
Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma.
Mikles B; Levine J; Gindin T; Bhagat G; Satwani P
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e85-7. PubMed ID: 23588340
[TBL] [Abstract][Full Text] [Related]
23. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
[TBL] [Abstract][Full Text] [Related]
24. Management of Anaplastic Large Cell Lymphoma.
Chihara D; Fanale MA
Hematol Oncol Clin North Am; 2017 Apr; 31(2):209-222. PubMed ID: 28340874
[TBL] [Abstract][Full Text] [Related]
25. Update on the Treatment of Anaplastic Large Cell Lymphoma.
Vu K; Ai W
Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
[TBL] [Abstract][Full Text] [Related]
27. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
28. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
[TBL] [Abstract][Full Text] [Related]
29. Recurrent ALK-negative anaplastic large T-cell lymphoma presenting as necrotizing vasculitis.
Nambudiri VE; Aboutalebi A; Granter SR; Saavedra A
Am J Dermatopathol; 2013 Jun; 35(4):512-6. PubMed ID: 23291583
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
32. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
33. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
Ansell SM
Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin: a review of its use in patients with hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure.
Garnock-Jones KP
Drugs; 2013 Mar; 73(4):371-81. PubMed ID: 23494187
[TBL] [Abstract][Full Text] [Related]
35. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
36. Severe cytokine release syndrome after the first dose of Brentuximab Vedotin in a patient with relapsed systemic anaplastic large cell lymphoma (sALCL): a case report and review of literature.
Alig SK; Dreyling M; Seppi B; Aulinger B; Witkowski L; Rieger CT
Eur J Haematol; 2015 Jun; 94(6):554-7. PubMed ID: 24913471
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin in systemic T-cell lymphoma.
Oki Y; Younes A
Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
[TBL] [Abstract][Full Text] [Related]
39. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
40. Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
Ogura M; Tobinai K; Hatake K; Ishizawa K; Uike N; Uchida T; Suzuki T; Aoki T; Watanabe T; Maruyama D; Yokoyama M; Takubo T; Kagehara H; Matsushima T
Cancer Sci; 2014 Jul; 105(7):840-6. PubMed ID: 24814862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]